Core Insights - Lantheus Holdings, Inc. announced the presentation of new data on florbetaben F18 at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference, scheduled for December 1-4 in San Diego, CA [1] Group 1: Presentation Details - The poster presentation will take place on December 3, 2025, from 7:15 AM to 5:30 PM PT, under session number 06 titled "Clinical Trials: Imaging" [2] - The poster is titled "Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab" and is numbered P184, presented by Marianne Chapleau from Life Molecular Imaging [2] Group 2: Product Information - Neuraceq (florbetaben F 18 injection) is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment [2] - The overall safety profile of Neuraceq is based on data from 1,090 administrations to 872 subjects, with common adverse reactions including injection site pain (3.4%), erythema (1.7%), and irritation (1.1%) [6] Group 3: Company Overview - Lantheus is a leading radiopharmaceutical-focused company that has been providing solutions for nearly 70 years, enabling the evaluation of Alzheimer's disease and other cognitive decline causes [7][8] - The company is headquartered in Massachusetts and has offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom [8]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Nationally ranked stock picker for 30 years. Victory Formation and Bottom Fishing Club quant-sort pioneer.....Paul Franke is a private investor and speculator with 39 years of trading experience. Mr. Franke was Editor and Publisher of the Maverick Investor® newsletter during the 1990s, widely quoted by CNBC®, Barron’s®, the Washington Post® and Investor’s Business Daily®. Paul was consistently ranked among top investment advisors nationally for stock market and commodity macro views by Timer Digest® during ...

Nationally ranked stock picker for 30 years. Victory Formation and Bottom Fishing Club quant-sort pioneer.....Paul Franke is a private investor and speculator with 39 years of trading experience. Mr. Franke was Editor and Publisher of the Maverick Investor® newsletter during the 1990s, widely quoted by CNBC®, Barron’s®, the Washington Post® and Investor’s Business Daily®. Paul was consistently ranked among top investment advisors nationally for stock market and commodity macro views by Timer Digest® during ...

Core Points - The Gross Law Firm has issued a notice to shareholders of Lantheus Holdings, Inc. regarding a class action lawsuit related to misleading statements about the company's revenue outlook and market conditions [1][3] - The class period for the lawsuit is from February 26, 2025, to August 5, 2025, during which shareholders are encouraged to register for potential recovery [3][4] - Allegations include that Lantheus misrepresented its understanding of the competitive dynamics and pricing of its product Pylarify, leading to inflated stock prices [3] Summary by Sections Class Action Details - Shareholders who purchased shares of Lantheus during the specified class period are invited to contact the Gross Law Firm for possible lead plaintiff appointment [1][4] - The deadline for shareholders to register for the class action is November 10, 2025 [4] Allegations Against Lantheus - The complaint alleges that Lantheus made false statements regarding its revenue projections and growth potential, while downplaying risks from competition and market fluctuations [3] - The company's optimistic reports on Pylarify's sales growth were found to be misleading, as they did not accurately reflect market conditions [3] Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies engage in responsible business practices [5] - The firm seeks recovery for investors who suffered losses due to misleading statements that artificially inflated stock prices [5]

Nov 10, 2025 11:20 AM Eastern Standard Time LNTH FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Lantheus Investors Have Opportunity to Lead Class Action Lawsuit Share Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Lantheus between November 6, 2024 and August 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi ...

Core Viewpoint - Rosen Law Firm is urging investors of Lantheus Holdings, Inc. to secure legal counsel before the November 10, 2025 deadline for a securities class action lawsuit related to the company's performance during the specified class period [1][3]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by the November 10, 2025 deadline to serve as lead plaintiff [3][5]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy, which ultimately harmed investors when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on November 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Lantheus provided misleading statements regarding the competitive position of its product, Pylarify, while failing to disclose critical information about pricing and market dynamics [5]. - It is claimed that Lantheus's early 2025 price increase, despite previous price erosion, created opportunities for competitive pricing that jeopardized Pylarify's market position and revenue potential [5].

Core Points - Rosen Law Firm is reminding investors of Lantheus Holdings, Inc. about the November 10, 2025 deadline to join a securities class action lawsuit related to the company's stock performance during the Class Period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased Lantheus securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit claims that Lantheus made overwhelmingly positive statements while concealing material adverse facts about Pylarify's market position, which led to investor damages when the truth was revealed [5].

Core Viewpoint - Lantheus Holdings, Inc. is facing a securities class action lawsuit due to allegations of providing misleading statements regarding its product Pylarify, with a lead plaintiff deadline set for November 10, 2025 [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, and may be entitled to compensation without upfront fees [2][5]. - A lawsuit has already been filed, and interested parties must act by the November 10, 2025 deadline to serve as lead plaintiff [3][5]. Group 2: Allegations Against Lantheus - The lawsuit claims that Lantheus made overly positive statements while concealing material adverse facts about Pylarify's competitive position [5]. - It is alleged that Lantheus failed to adequately assess pricing dynamics and that a price increase in early 2025, despite previous price erosion, risked Pylarify's market position and revenue potential [5]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel, highlighting its track record in securities class actions and significant settlements [4]. - The firm has recovered hundreds of millions for investors, including over $438 million in 2019, and has been consistently ranked among the top firms in this area since 2013 [4].